Shaw Joanna E T, Pasipanodya Jotam G, Gumbo Tawanda
From University of Texas Southwestern Medical Center, Dallas, Texas.
Medicine (Baltimore). 2010 May;89(3):189-195. doi: 10.1097/MD.0b013e3181df9070.
The long-term outcomes of patients with tuberculous meningitis treated with modern chemotherapy are poorly defined. We conducted this retrospective case-control study to determine the long-term survival in patients with proven tuberculous meningitis treated by directly observed therapy in the state of Texas. The patients had been diagnosed and treated for tuberculous meningitis between 2000 and 2005 in the state of Texas. Cases were patients with microbiologically proven tuberculous meningitis; controls were patients in whom Mycobacterium tuberculosis could not be isolated but met the Centers for Diseases Control and Prevention (CDC) criteria for non-proven tuberculous meningitis. There were 135 cases and 75 controls, with average observation periods of 3.76 +/- 2.63 years and 4.51 +/- 2.09 years, respectively. At the end of the observation period, 39.76% of cases were still alive compared to 85.07% of controls. The long-term outlook in patients with proven tuberculous meningitis adequately treated with current standard tuberculous therapy is bleak. A re-examination of treatment strategies is urgently needed.
采用现代化疗方法治疗的结核性脑膜炎患者的长期预后情况尚不明确。我们开展了这项回顾性病例对照研究,以确定在得克萨斯州接受直接观察治疗的确诊结核性脑膜炎患者的长期生存率。这些患者于2000年至2005年期间在得克萨斯州被诊断并接受结核性脑膜炎治疗。病例组为微生物学确诊的结核性脑膜炎患者;对照组为未分离出结核分枝杆菌但符合美国疾病控制与预防中心(CDC)非确诊结核性脑膜炎标准的患者。共有135例病例和75例对照,平均观察期分别为3.76±2.63年和4.51±2.09年。在观察期结束时,病例组39.76%的患者仍存活,而对照组这一比例为85.07%。采用当前标准抗结核疗法充分治疗的确诊结核性脑膜炎患者的长期前景不容乐观。迫切需要重新审视治疗策略。